Human/Mouse EZH2 Antibody

Detection of Human and Mouse EZH2 by Western Blot. Western blot shows lysates of HeLa human cervical epithelial carcinoma cell line, Jurkat human acute T cell leukemia cell line, and mouse spleen tissue. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human/Mouse EZH2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4767) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for EZH2 at approximately 80 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8.

Detection of Human EZH2/KMT6 by Western Blot Measurement of EZH2 protein under conditions of SIRT1 knockdown. SIRT1 knockdown in Caco-2 cells was achieved using two different siRNAs and protein was analysed by Western blotting using anti-EZH2 antibody (a) or anti-SIRT1 antibody (to confirm efficacy of knockdown) (b). Blots were probed with anti-alpha -tubulin antibody to confirm equal protein loading and transfer. Approximately 10 μg of protein was loaded in each lane. Three biological replicates are presented for each condition. Approximate molecular weights are indicated Image collected and cropped by CiteAb from the following publication (https://humgenomics.biomedcentral.com/articles/10.1186/s40246-015-0036-0), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human EZH2/KMT6 by Western Blot EZH2 elevates at S phase in hDPCs and interacts with PCNA. a Schematic chart illustrating the serum deprivation approach used for G0/G1 phase synchronization of hDPCs. b Western blot shows the expression of EZH2 in hDPCs at the indicated time points after release from serum deprivation. Immunofluorescence shows the subcellular localization of EZH2 in hDPCs in G1 or S phase. c Co-immunoprecipitation (Co-IP) of EZH2 and PCNA in hDPCs (synchronized at S phase) and proximity ligation assay (PLA) after co-incubating anti-EZH2 and anti-PCNA antibodies in hDPCs in S phase. IgGs were used as control antibodies for the IP. Antibodies used for IP and western blot are labelled as IP and IB, respectively. Total lysate (10 μg) was used as an input control. Scale bars represent 20 μm Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30071900), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human EZH2/KMT6 by Proximity Ligation Assay EZH2 elevates at S phase in hDPCs and interacts with PCNA. a Schematic chart illustrating the serum deprivation approach used for G0/G1 phase synchronization of hDPCs. b Western blot shows the expression of EZH2 in hDPCs at the indicated time points after release from serum deprivation. Immunofluorescence shows the subcellular localization of EZH2 in hDPCs in G1 or S phase. c Co-immunoprecipitation (Co-IP) of EZH2 and PCNA in hDPCs (synchronized at S phase) and proximity ligation assay (PLA) after co-incubating anti-EZH2 and anti-PCNA antibodies in hDPCs in S phase. IgGs were used as control antibodies for the IP. Antibodies used for IP and western blot are labelled as IP and IB, respectively. Total lysate (10 μg) was used as an input control. Scale bars represent 20 μm Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30071900), licensed under a CC-BY license. Not internally tested by R&D Systems.